secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-04-10T23:59:59+00:00
Accession:  0001437749-24-011573
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar initiates Phase 1 dosimetry trial for MNPR-101-Zr in advanced cancers
-----------------------------------------------------------------------------

- Trial open for enrollment at Melbourne Theranostic Innovation Centre; led by Prof. Rodney Hicks.
- Evaluating safety/dosimetry in up to 12 advanced cancer patients using total-body PET/CT scanner.
- MNPR-101 targets uPAR expressed on pancreatic, breast, colorectal, and bladder tumors.
- Preclinical data show specific tumor uptake; if Phase 1 positive, plan to test MNPR-101 with therapeutic Ac-225.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924011573/0001437749-24-011573-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924011573/mnpr20240402_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-011573

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer